Free Trial

Enzo Biochem (ENZ) Competitors

Enzo Biochem logo
$1.14
0.00 (0.00%)
(As of 10/31/2024 ET)

ENZ vs. SERA, LFMD, BDSX, ATPC, PIII, CORBF, QIPT, EUDA, MGRX, and XGN

Should you be buying Enzo Biochem stock or one of its competitors? The main competitors of Enzo Biochem include Sera Prognostics (SERA), LifeMD (LFMD), Biodesix (BDSX), Agape ATP (ATPC), P3 Health Partners (PIII), Global Cord Blood (CORBF), Quipt Home Medical (QIPT), EUDA Health (EUDA), Mangoceuticals (MGRX), and Exagen (XGN). These companies are all part of the "healthcare" industry.

Enzo Biochem vs.

Sera Prognostics (NASDAQ:SERA) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Enzo Biochem has a net margin of 134.17% compared to Sera Prognostics' net margin of 0.00%. Enzo Biochem's return on equity of -21.50% beat Sera Prognostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sera PrognosticsN/A -46.71% -35.01%
Enzo Biochem 134.17%-21.50%-14.95%

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 36.9% of Enzo Biochem shares are held by institutional investors. 15.8% of Sera Prognostics shares are held by insiders. Comparatively, 15.5% of Enzo Biochem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Enzo Biochem has higher revenue and earnings than Sera Prognostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sera Prognostics$107K2,398.20-$36.24M-$0.98-7.85
Enzo Biochem$33.34M1.77$20.29MN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sera Prognostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Enzo Biochem
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Enzo Biochem received 202 more outperform votes than Sera Prognostics when rated by MarketBeat users. Likewise, 55.64% of users gave Enzo Biochem an outperform vote while only 38.46% of users gave Sera Prognostics an outperform vote.

CompanyUnderperformOutperform
Sera PrognosticsOutperform Votes
10
38.46%
Underperform Votes
16
61.54%
Enzo BiochemOutperform Votes
212
55.64%
Underperform Votes
169
44.36%

In the previous week, Enzo Biochem had 6 more articles in the media than Sera Prognostics. MarketBeat recorded 8 mentions for Enzo Biochem and 2 mentions for Sera Prognostics. Sera Prognostics' average media sentiment score of 0.47 beat Enzo Biochem's score of 0.34 indicating that Sera Prognostics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sera Prognostics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enzo Biochem
0 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sera Prognostics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, Enzo Biochem has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500.

Summary

Enzo Biochem beats Sera Prognostics on 8 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENZ vs. The Competition

MetricEnzo BiochemMedical laboratories IndustryMedical SectorNYSE Exchange
Market Cap$58.92M$2.47B$5.36B$19.17B
Dividend YieldN/A1.67%5.22%3.52%
P/E RatioN/A33.47131.9331.74
Price / Sales1.77235.371,440.1517.87
Price / CashN/A507.7939.0620.46
Price / Book0.724.674.745.38
Net Income$20.29M-$31.39M$115.43M$984.37M
7 Day Performance-1.29%-1.01%-0.86%-0.54%
1 Month Performance2.23%-3.75%3.61%-0.97%
1 Year Performance-14.55%43.32%38.90%29.31%

Enzo Biochem Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENZ
Enzo Biochem
0.5499 of 5 stars
$1.15
flat
N/A-17.7%$58.92M$33.34M0.00520Dividend Announcement
Analyst Forecast
News Coverage
SERA
Sera Prognostics
0.2864 of 5 stars
$6.70
-3.7%
N/A+370.5%$223.58M$310,000.00-6.84120News Coverage
Gap Down
LFMD
LifeMD
2.153 of 5 stars
$4.43
+3.3%
$12.00
+170.9%
-33.0%$184.98M$178.28M-6.33230Upcoming Earnings
Short Interest ↑
News Coverage
BDSX
Biodesix
3.3011 of 5 stars
$1.60
-2.7%
$3.06
+91.8%
+12.2%$182.92M$60.90M-3.47220Upcoming Earnings
ATPC
Agape ATP
0.3978 of 5 stars
$1.88
-4.1%
N/A-88.3%$144.71M$1.38M-3.1340Positive News
Gap Up
High Trading Volume
PIII
P3 Health Partners
3.1221 of 5 stars
$0.44
+8.2%
$4.50
+924.1%
-73.8%$138.90M$1.40B-0.68500Positive News
CORBF
Global Cord Blood
N/A$1.00
-20.0%
N/A+0.0%$121.55M$196.12M0.001,202Negative News
Gap Down
QIPT
Quipt Home Medical
2.8664 of 5 stars
$2.76
+1.8%
$6.25
+126.4%
-41.7%$117.50M$255.81M-25.091,200News Coverage
EUDA
EUDA Health
1.5152 of 5 stars
$4.75
+1.1%
N/A+508.3%$116.98M$3.71M0.002Positive News
MGRX
Mangoceuticals
1.601 of 5 stars
$2.44
+0.8%
N/A-98.5%$60.56M$866,792.00-0.383Upcoming Earnings
XGN
Exagen
4.4687 of 5 stars
$2.71
+0.7%
$7.00
+158.3%
+51.2%$47.13M$52.55M-2.79220

Related Companies and Tools


This page (NYSE:ENZ) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners